Program
Budesonide
Also written as “budesonide”, “budesonide/formoterol” and “BGF MDI 320/14.4/9.6 μg”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Eosinophilic Esophagitis · Colitis, Ulcerative · Glomerulonephritis, IGA, led by 35 companies.
Drug pageBudesonide: every studyMany companies study it; this page follows only the 163 they lead. All 307 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 692 open or running | phase 4since Sep 27, 2005 | Sep 13, 2005 | May 31, 2027phase 4 · NCT07073950 |
| Dr. Falk Pharma | 171 open or running | phase 3since Mar 7, 2006 | Mar 7, 2006 | Dec 2026phase 3 · NCT06596252 |
| Bausch Health Companiesits history only | 91 open or running | phase 4since Mar 17, 2020 | May 14, 2008 | Dec 2026phase 4 · NCT04314375 |
| Takedaits history only | 60 open or running | phase 3since Nov 4, 2015 | Sep 29, 2008 | none ahead |
| AbbVieits history only | 50 open or running | phase 3since Dec 5, 2007 | Oct 30, 2007 | none ahead |
| Calliditas Therapeutics ABits history only | 51 open or running | phase 4since Nov 20, 2024 | Oct 5, 2008 | Mar 2027phase 4 · NCT06712407 |
| Intech Biopharmits history only | 50 open or running | phase 2since Jun 11, 2014 | Jun 11, 2014 | none ahead |
| Chenpon Pharmaceuticalits history only | 30 open or running | phase 3since Aug 24, 2026 | Aug 24, 2026 | none ahead |
| Eurofarma Laboratoriosits history only | 30 open or running | phase 3since Oct 23, 2009 | Oct 23, 2009 | none ahead |
| Novartisits history only | 30 open or running | phase 4since Feb 15, 2013 | Feb 15, 2013 | none ahead |
| Orion Corporation, Orion Pharmaits history only | 30 open or running | phase 2since Aug 24, 2009 | Aug 24, 2009 | none ahead |
| Padagisits history only | 30 open or running | phase 3since Sep 28, 2011 | Sep 28, 2011 | none ahead |
| Aquilon Pharmaceuticalsits history only | 20 open or running | phase 2since May 31, 2021 | May 31, 2021 | none ahead |
| Bond Avillion 2 Development LPits history only | 20 open or running | phase 3since Nov 30, 2018 | Nov 30, 2018 | none ahead |
| Ferring Pharmaceuticalsits history only | 20 open or running | phase 3since Jan 22, 2018 | Jan 22, 2018 | none ahead |
| Ligand Pharmaceuticalsits history only | 20 open or running | phase 2since Jul 13, 2009 | Jul 13, 2009 | none ahead |
| Pari Pharmaits history only | 20 open or running | phase 2since Sep 4, 2013 | Sep 4, 2013 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 3since Feb 12, 2014 | Feb 12, 2014 | none ahead |
| Triastek, lnc.its history only | 22 open or running | phase 1since Oct 13, 2026 | Oct 13, 2026 | Dec 2026phase 1 · NCT07897240 |
| Vecturaits history only | 20 open or running | phase 1since Jan 12, 2018 | Jan 12, 2018 | none ahead |
| Zambon SpAits history only | 20 open or running | phase 1since Sep 2, 2014 | Sep 2, 2014 | none ahead |
| Abbottits history only | 10 open or running | phase 1since Jul 26, 2022 | Jul 26, 2022 | none ahead |
| Ache Laboratorios Farmaceuticosits history only | 10 open or running | phase 3since Jul 25, 2016 | Jul 25, 2016 | none ahead |
| Activaeroits history only | 10 open or running | phase 2since Sep 10, 2010 | Sep 10, 2010 | none ahead |
| Bazell Pharmaits history only | 10 open or running | phase 2since Jan 3, 2022 | Jan 3, 2022 | none ahead |
| Chiesi Farmaceuticiits history only | 10 open or running | phase 3since May 18, 2007 | May 18, 2007 | none ahead |
| Ciplaits history only | 10 open or running | phase 3since Mar 31, 2022 | Mar 31, 2022 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Apr 18, 2021 | Apr 18, 2021 | none ahead |
| Hamad Medicalits history only | 11 open or running | phase 3since May 25, 2015 | May 25, 2015 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 4since Oct 17, 2019 | Oct 17, 2019 | none ahead |
| Kindeva Drug Deliveryits history only | 10 open or running | phase 3since Jan 6, 2017 | Jan 6, 2017 | none ahead |
| Lunan Pharmaceutical Groupits history only | 10 open or running | no phasesince Mar 29, 2025 | Mar 29, 2025 | none ahead |
| Marinomed Biotechits history only | 10 open or running | phase 3since Nov 21, 2018 | Nov 21, 2018 | none ahead |
| Rafa Laboratoriesits history only | 10 open or running | phase 3since Aug 9, 2005 | Aug 9, 2005 | none ahead |
| Unither Pharmaceuticals, Franceits history only | 10 open or running | phase 1since Sep 6, 2024 | Sep 6, 2024 | none ahead |
Also a collaborator on its studies: Parexel, Fortrea, Takeda Development Center Americas, Iqvia Pty, Premier, Hikma Pharmaceuticals, Cosmo Technologies, MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan, Q-Pharm Pty and Kyowa Kirin.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Dr. Falk Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Mar 7, 2006.
- Sep 3, 20082 phase 3 studiesNCT00747110, NCT00746486
- Jan 22, 2009Phase 2 study in Radiation ProctitisNCT00828230 · 17 enrolled · Germany
- Feb 5, 2009Phase 3 study in Hepatitis, AutoimmuneNCT00838214 · 208 enrolled · Germany
- Apr 22, 2009Phase 3 study in Oral Chronic Graft vs Host DiseaseNCT00887263 · 186 enrolled · Germany, Israel
- Mar 12, 2010Phase 3 study in Crohn DiseaseNCT01086553 · 471 enrolled · Germany
- Sep 23, 2010Phase 3 study in Colitis, LymphocyticNCT01209208 · 57 enrolled · Germany
- Jan 14, 2011Phase 3 study in Colitis, CollagenousNCT01278082 · 92 enrolled · Germany, Sweden
- Oct 9, 2013Phase 2 study in ProctitisNCT01966783 · 320 enrolled · Germany
- May 14, 2014Phase 3 study in Incomplete Microscopic ColitisNCT02142634 · 44 enrolled · Germany, Sweden
- Oct 29, 2014Phase 2 study in Eosinophilic EsophagitisNCT02280616 · 76 enrolled · Germany
- Apr 30, 2015Phase 3 study in Eosinophilic EsophagitisNCT02434029 · 88 enrolled · Germany
- Jul 7, 2015Phase 3 study in Eosinophilic EsophagitisNCT02493335 · 204 enrolled · Germany
- Sep 14, 2015Phase 2 study in Colitis, UlcerativeNCT02550418 · 60 enrolled · Germany
- Sep 11, 2024Phase 3 study in Eosinophilic EsophagitisNCT06596252 · 308 enrolled · United States, Spain
Ahead
- Dec 2026Primary completion: phase 3 study in Eosinophilic EsophagitisNCT06596252
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
| Triamcinolone Acetoniderule | clearside-biomedical-inc | phase 3 | 20 |
Studies
All 17 Dr. Falk Pharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06596252Eosinophilic Esophagitis · United States, Spain | 3 | Active, not recruiting | Dec 2026 | 308 |
| NCT02550418Colitis, Ulcerative · Germany | 2 | Completed | Mar 2017 | 60 |
| NCT02493335Eosinophilic Esophagitis · Germany | 3 | Completed | Nov 28, 2018 | 204 |
| NCT02434029Eosinophilic Esophagitis · Germany | 3 | Completed | Aug 4, 2016 | 88 |
| NCT02280616Eosinophilic Esophagitis · Germany | 2 | Completed | Apr 2013 | 76 |
| NCT02142634Incomplete Microscopic Colitis · Germany, Sweden | 3 | Completed | Feb 2020 | 44 |
| NCT01966783Proctitis · Germany | 2 | Completed | Aug 2015 | 320 |
| NCT01278082Colitis, Collagenous · Germany, Sweden | 3 | Completed | Mar 2013 | 92 |
| NCT01209208Colitis, Lymphocytic · Germany | 3 | Completed | Jun 2017 | 57 |
| NCT01086553Crohn Disease · Germany | 3 | Completed | May 2012 | 471 |
| NCT00887263Oral Chronic Graft vs Host Disease · Germany, Israel | 3 | Completed | Oct 2015 | 186 |
| NCT00838214Hepatitis, Autoimmune · Germany | 3 | Completed | Dec 2008 | 208 |
| NCT00828230Radiation Proctitis · Germany | 2 | Terminated | Aug 2011 | 17 |
| NCT00747110Colitis, Ulcerative · Germany | 3 | Completed | Aug 2008 | 343 |
| NCT00746486Liver Cirrhosis, Biliary · France, Germany | 3 | Terminated | Oct 2019 | 62 |
| NCT00450086Colitis, Collagenous · Germany | 3 | Completed | Jun 2011 | 92 |
| NCT00300118Crohn Disease · Germany | 3 | Completed | May 2008 | 311 |
How it is read
Names in the registry
- “Budesonide”, 45 entries
- “budesonide”, 18 entries
- “budesonide/formoterol”, 10 entries
- “BGF MDI 320/14.4/9.6 μg”, 6 entries
- “BFF MDI 320/9.6 μg”, 5 entries
Conditions, from the studies’ own filings
- Asthma, 75 studies
- Pulmonary Disease, Chronic Obstructive, 23 studies
- Eosinophilic Esophagitis, 10 studies
- Colitis, Ulcerative, 9 studies
- Glomerulonephritis, IGA, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.